目的：极度右心室肥厚是肥厚型心肌病（HCM）中非常罕见的一种特殊形态，表现为右心室壁的显著肥厚，既往只有散在的病例报告。全基因组测序是最新的二代测序技术，尚未有将全基因组测序用于HCM的研究。本文探究HCM伴有极度右心室肥厚患者的遗传学特点。

目的：左心室中部肥厚型梗阻性心肌病（MVHOCM）是肥厚型心肌病的一种较为少见的类型。本文旨在比较酒精室间隔消融（ASA）以及心肌切除术治疗MVHOCM的效果。<br>　　方法：对在阜外心血管病医院接受ASA和心肌切除术治疗的MVHOCM患者的术前及术后资料进行分析。

目的：探讨心肌隐窝的空间分布与肥厚型心肌病相关基因突变的关系。<br>　　方法：以“hypertrophiccardiomyopathy”和“myocardialcrypts”为关键词检索PUBMED。从入选文献中提取相关数据。利用SPSS 16.0进行统计学分析。

肥厚型心肌病（hypertrophic cardiomyopathy，HCM）是一种主要由心肌肌小节基因突变导致的，以无明显诱因下出现的以非对称性室间隔肥厚（≥15 mm）为主要病理表现，以胸闷、胸痛、黑朦、晕厥及心源性猝死为主要临床表现的原发性心肌病，是青少年心源性猝死的首要因素。

目的：分析和总结女性心尖肥厚型心肌病（ApHCM）患者临床及超声心动图特点。<br>　　方法：利用SPSS16.0软件包分析1999-1至2006-1期间连续登记注册的我院住院女性ApHCM患者的临床及超声心动图资料。

目的：心肌细胞中的氨基酸末端脑钠肽前体（NT-pro-BNP）在心肌受到牵张、室壁张力增大时释放增加。NT-pro-BNP在肥厚型心肌病（HCM）患者中显著升高，是HCM预后的独立预测因子。本文研究在左室极度肥厚患者（室壁厚度≥30 mm）与轻、中度肥厚患者（室壁厚度15 mm~29 mm） NT-pro-BNP水平的差异以及与室壁厚度的关系。

OBJECTIVE To evaluate the efficacy and tolerability of the fixed combination of amlodipine 5 mg/benazepril 10 mg once-daily therapy, compared with benazepril, 10 mg, monotherapy in patients with mild and moderate hypertension, and to evaluate the 24 h antihypertensive efficacy and the duration of action by ambulatory blood pressure monitoring. METHODS In a multicenter, randomized, double-blind, parallel controlled trial, 356 cases of hypertensive patients after 2 weeks wash-out, and then given 4 weeks of benazepril 10 mg monotherapy, 220 patients with mean seated diastolic blood pressure (SeDBP) remained ≥ 90 mm Hg (1 mm Hg = 0.133 kPa) were randomly divided into benazepril 10 mg/amlodipine 5 mg (BZ10/AML5) fixed-dose combination therapy group (once a day, n = 113), and benazepril monotherapy group (daily 20 mg, n = 107). In the two groups the patients with SeDBP ≥ 90 mm Hg were doubled the dosage of the initial regimen at the end of 4-week treatment for additional 4 weeks, and the patients with SeDBP < 90 mm Hg remained the initial regimen for additional 4 weeks. The primary endpoint was to evaluate the improvement of SeDBP at the end of 8-week treatment. There were 74 patients (the combination therapy group n = 38, monotherapy therapy group n = 36) completed the 24 h ambulatory blood pressure monitoring which was included in the final efficacy analysis. RESULTS The randomized, double-blind treatment for 8 weeks, the mean value of SeDBP reduction, the reaching target blood pressure rate and total successful response rate to the treatment (a SeDBP < 90 mm Hg or a decrease of 10 mm Hg or more from baseline) were (11.7 ± 6.8) mm Hg, 65.7% and 88.5% in the combination therapy group, respectively, and were (7.7 ± 6.9) mm Hg, 35.5% and 65.5% in the monotherapy group, respectively. There were statistically significant difference between the combination therapy and the monotherapy groups in all the 3 indexs (P < 0.001). The fixed combination significantly reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP) values throughout the 24 h. The trough to peak ratios of DBP/SBP in the fixed compound of benazepril/amlodipine (10 mg/5 mg) and benazepril (20 mg) alone were 83.1%/76.0% and 85.8%/79.5%, respectively. Adverse events rates were 16.8% in the combination therapy group and 35.5% in the monotherapy group (P < 0.001). CONCLUSIONS The combination therapy with benazepril/amlodipine was superior to benazepril monotherapy and was well tolerated in patients with essential hypertension and allowing a satisfactory BP control for 24 hours.

Objective: To study the effects of sustained-release tablets of metoprolol on HRV of essential hypertension patients.Methods: After 2-week drug wash-out,94 patients with essential mild-to-moderate hypertension received once-daily sustained-release tablets of fumarate metoprolol 95mg per day or sustained-release tablets of tartrate metoprolol 100mg per day for 8 weeks.The 24-hour ambulatory ECG was performed before and after 8 weeks treatment.Spectum of heart rate variability(24hours time domain and 5 minutes frequency domain) of total patients taking drugs was analyzed.Results: There was no significant differences in HRV before and after treatment between fumarate metoprolol and tartrate metoprolol.The 24-h average heart rate in all patients(n=94) was(76.27±8.18) bpm and(69.29±6.48) bpm after 8 weeks treatment,P0.0001.All patients had PNN50 increased,(5.6±4.8) ms vs(8.5±7.2)ms(P0.0001),while HF and LF/HF also significantly increased,(88.8±92.8) Hz vs(127.3±127.1) Hz(P=0.007) and(2.9±2.0) vs(2.1±2.1)(P=0.002) respectively.Conclusion: Sustained-release tablet of metoprolol not only decreases blood pressure but also shows beneficial effect on HRV.The acid radical doesn't have influence on the effect of sustained-release tablets of metoprolol on HRV in patients with primary hypertension.

The intravascular ultrasound (IVUS) imaging may play an important role in assessing the results of percutaneous transluminal coronary angioplasty (PTCA). The purpose of this study is to evaluate the effects of PTCA by IVUS further. The vessel diameter, luminal area, plaque area, and plaque thickness were observed and measured in 8 patients before and after PTCA. Results showed that the diameters of vessels and the lumen areas were significantly increased after balloon angioplasty (P < 0.001). There were no significant differences in plaque area before and after PTCA. IVUS can clearly distinguish the vessel plaque, calcification, dissection and muscular media. Conclusion: after coronary balloon angioplasty, IVUS provides more qualitative and quantitative information on the diameter, lumen area, plaque geometry, and composition than angiography. It added some diagnostic information undetected by standard angiography. This information could be used to enhance the understanding of success, failure, and immediate complications after PTCA in patients with complex coronary disease.